Subscribe to receive future Ambry updates!
Letter from Tom Schoenherr, CEO: Definitive Agreement for Acquisition of Ambry Genetics by Tempus AI
Ambry Genetics Announces New Hereditary Cancer Test Menu at NSGC Annual Conference
Ambry Genetics Announces New Multiomic Exome Test for Improved Rare Disease Detection
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists
Ambry Genetics Unveils at ASHG New Insights on the Use of Multiomic Testing in 43,000 Patient Study
LifeStrands Genomics and Ambry Genetics to Provide Laboratory Testing for Clinical Implementation Pilots in Phase II of Singapore’s National Precision Medicine Programme
Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East
Ambry’s New Reproductive Health Program Uses Digital Platform to Make It Easier for Patients to Access Genetic Screening Before and During Pregnancy
Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone
Start your search...